This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | MicrobiomeTrials
← Back to trials NCT03641313
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Completed PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2020-11-16Est. Completion: 2024-07-01
Enrollment target: 17 participantsLocations City of Hope Comprehensive Cancer Center, Duarte, California, United States Los Angeles General Medical Center, Los Angeles, California, United States USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States University of California Davis Comprehensive Cancer Center, Sacramento, California, United States UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States Northwestern University, Chicago, Illinois, United States University of Kansas Clinical Research Center, Fairway, Kansas, United States HaysMed, Hays, Kansas, United States Lawrence Memorial Hospital, Lawrence, Kansas, United States Other microbiome trials you might be interested in Advanced Esophageal Adenocarcinoma Advanced Gastric Adenocarcinoma Advanced Gastroesophageal Junction Adenocarcinoma Clinical Stage II Esophageal Adenocarcinoma AJCC v8 Clinical Stage III Esophageal Adenocarcinoma AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Metastatic Esophageal Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
Mercy Hospital Pittsburg, Pittsburg, Kansas, United States
Salina Regional Health Center, Salina, Kansas, United States
University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
University Health Truman Medical Center, Kansas City, Missouri, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States
Wake Forest University at Clemmons, Clemmons, North Carolina, United States
Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States Unresectable Esophageal Adenocarcinoma
Unresectable Gastric Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to pacli…
Little Rock, United States Est. completion Oct 31, 2027
Clinical Stage 0 Gastric Cancer AJCC v8 Clinical Stage I Gastric Cancer AJCC v8 Clinical Stage II Gastric Cancer AJCC v8 Clinical Stage IIA Gastric Cancer AJCC v8 Clinical Stage IIB Gastric Cancer AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Gastric Adenocarcinoma Pathologic Stage 0 Gastric Cancer AJCC v8 Pathologic Stage I Gastric Cancer AJCC v8 Pathologic Stage IA Gastric Cancer AJCC v8 Pathologic Stage IB Gastric Cancer AJCC v8 Pathologic Stage II Gastric Cancer AJCC v8 Pathologic Stage IIA Gastric Cancer AJCC v8 Pathologic Stage IIB Gastric Cancer AJCC v8 Pathologic Stage III Gastric Cancer AJCC v8 Pathologic Stage IIIA Gastric Cancer AJCC v8 Pathologic Stage IIIB Gastric Cancer AJCC v8 Pathologic Stage IIIC Gastric Cancer AJCC v8
This phase II trial studies how well an early recovery after surgery protocol works in enhancing quality of life in part…
Duarte, United States Est. completion Jan 18, 2023
Clinical Stage II Esophageal Adenocarcinoma AJCC v8 Clinical Stage III Esophageal Adenocarcinoma AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Locally Advanced Esophageal Adenocarcinoma Locally Advanced Gastric Adenocarcinoma Locally Advanced Gastroesophageal Junction Adenocarcinoma Metastatic Esophageal Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Unresectable Esophageal Adenocarcinoma Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Carcinoma
This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the t…
Chicago, United States Est. completion Sep 9, 2030